Dr. Sapna Patel, MD

• Medical Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• University Of Texas Medical Branch

  Medical School, 2005

• A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma, 2017-06-13

• Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results, 2023-03-30

• Intermittent MEK inhibition for the treatment of metastatic uveal melanoma, 2022-09-29

• Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-a in patients with metastatic melanoma, 2014-12-20

• Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma, 2023-03-09

• Adjuvant pembrolizumab versus interferon alfa-2b or ipilimumab in resected high-risk melanoma, 2022-03-01

• Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM, 2016-10-29

• Case Report: Neuromyelitis Optica After Treatment of Uveal Melanoma With Nivolumab and Ipilimumab, 2022-03-23

• Adjuvant Ipilimumab in High-Risk Uveal Melanoma, 2019-01-29

• Beyond BRAFV600: clinical mutation panel testing by next-generation sequencing in advanced melanoma, 2014-08-22

• Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma, 2017-04-07

• Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade, 2016-06-14

• BRAF, NRAS,ANDKITSEQUENCING ANALYSIS OF SPINDLE CELL MELANOMA, 2012-07-19

• Targeting IRS-1/2 in Uveal Melanoma Inhibits In Vitro Cell Growth, Survival and Migration, and In Vivo Tumor Growth, 2022-12-19

• A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma, 2016-09-20

• Hypoxia-Driven Immunosuppressive Metabolites in the Tumor Microenvironment: New Approaches for Combinational Immunotherapy, 2018-07-16

• 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one National Harbor, MD, USA. 9-13 November 2016, 2016-11-16

• Presence of Circulating Tumor Cells Predates Imaging Detection of Relapse in Patients with Stage III Melanoma, 2023-07-15

• Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma, 2022-10-17

• Delayed systemic recurrence of uveal melanoma, 2015-05-05

• Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance, 2017-03-01

• Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma, 2022-05-02

• Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy, 2022-04-12

• Metastatic Risk Factors Associated with Class 1A Uveal Melanoma Patients, 2021-06-30

• Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies, 2021-03-05

• Prospective analysis of adoptive TIL therapy in patients with metastatic melanoma: response, impact of anti-CTLA4, and biomarkers to predict clinical outcome, 2018-05-30

• Phase I/II study of hepatic arterial infusion of nab-paclitaxel in patients with metastatic melanoma to the liver, 2018-02-05

• Neoadjuvant relatlimab and nivolumab in resectable melanoma, 2022-10-26

• Second Primary Malignancies in Patients With Melanoma Subtypes: Analysis of 120,299 Patients From the SEER Database (2000-2016), 2022-03-18

• Phase I Study of the Combination of Vemurafenib, Carboplatin, and Paclitaxel in Patients withBRAF-Mutated Melanoma and Other Advanced Malignancies, 2018-11-01

• Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition, 2019-02-18

• Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response, 2021-12-23

• BRAFmutation testing with a rapid, fully integrated molecular diagnostics system, 2015-07-27

• Utilizing T-cell activation signals 1, 2 and 3 for tumor-infiltrating lymphocytes (TIL) expansion: the advantage over the sole use of interleukin-2 in cutaneous and uveal melanoma, 2018-05-08

• Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund's adjuvant (IFA) for resected high-risk melanoma, 2021-08-19